Fast reading
- As a contract development and manufacturing organisation (CDMO), Lonza provides drug development and manufacturing services, helping take medicines, treatments and supplements from concept to commercialisation. It is well positioned to benefit from a secular outsourcing trend, as pharmaceutical companies increasingly rely on CDMOs.
- Lonza is an enabler of next‑generation healthcare, providing advanced manufacturing and technology platforms that help bring innovative therapies to market.
- It also contributes to addressing unmet global health needs. Progress against the UN Sustainable Development Goals (SDG) remains off track, reinforcing the need for scalable healthcare solutions.
Engagement commentary: Lonza Group
For more information on Sustainable Global Equity.
Share:
This information does not constitute a solicitation or offer to any person to buy or sell any related securities or financial instruments.
BD017775
